TickerGuard
Buy Day today: Neutral (46) Mixed market breadth · no major macro event

Growth

Matt Caruso: Sales Leader

23 Hits · last calculated November 2, 2026 Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Methodology & criteria

Matt Caruso's sales screen: 12-month relative strength above 75, revenue growth in the latest quarter above 40%, 12-month revenue growth above 40%, price above $20, and average volume (50 days) above 150,000 shares — market leaders whose growth is accelerating AND that the market is already rewarding. Source: fundamental data.

Global filters: market cap of $50B or less (mega caps are cut from every scanner); 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); names after a reverse split (distorted price history) are excluded.

🔔 Watch scanner

Terms in This Scanner Explained

(14)
ADR (Average Daily Range)
The average daily swing of a stock in percent - measured over 10 or 30 trading days (columns "ADR 10D/30D"). An ADR of 5% means: on a normal day the gap between the intraday low and high runs about 5%. Traders look for movement - that is why stocks with an ADR under 1% are filtered out globally. Scanners that run without the global filters still include them; that is noted below their hit list. Not to be confused with ADR meaning "American Depositary Receipt" (a US certificate for foreign shares) - here ADR always means the daily swing.
AI Classification
Our company-by-company assessment of the AI boom based on SEC filings (the last four quarterly 10-Q reports and two annual 10-K reports): "Sells AI" (AI is a revenue source), "Threatened" (AI is a concrete business risk), "Uses AI" (operational use), or "Neutral" (no material AI exposure). Every classification requires at least two direct quote citations - otherwise the column shows "-". Not a quality judgment or a buy recommendation; the full file is on the stock page, methodology at /stocks/ai-rating-methodology.
Analysis (Full Company Analysis)
If the Analysis column shows "Read," there is an in-depth TickerGuard company analysis for this stock: business model, scanner findings, quarterly results, evidence from SEC filings, plus opportunities and risks. One click opens it directly.
Avg/Yr 3Y (Average Annual Return)
The stock's average annual return over the past 3 years. Shows at a glance whether a stock delivers over the long run or just had a short hot streak.
Earnings Date
The date of the next quarterly earnings report. Price gaps in either direction are common around this date - that is why we color it red when it is 7 days away or less, and yellow when it is 14 days away or less: elevated risk for fresh positions.
EPS (Earnings per Share)
Quarterly earnings divided by the number of shares outstanding. The most important growth metric: if EPS rises strongly over several quarters, the company is earning more money per share.
Free Cash Flow (FCF)
Operating cash flow minus capital expenditures - the money left over for everything else (debt paydown, acquisitions, or buybacks). Consistently positive free cash flow is one of the most honest signs of a healthy business model.
Funda Rating (Fundamental Rating A+ to F)
Our proprietary fundamental rating from 0 to 100 points with a school-grade rank from A+ to F. 50 points is the average across the universe, 100 the best possible score. Every stock is scored against all others by percentile: growth in earnings and revenue, earnings surprises, analyst estimates, and quality criteria such as margins, cash flow, and balance-sheet strength. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below — A/A+ are the fundamentally strongest stocks in the universe.
Market Capitalization (Mkt Cap)
The market value of the company: share price x total shares outstanding, shown here in billions of dollars. Micro caps (< $0.3B) are small and volatile, mega caps (> $200B) are heavyweights. Our scanner universe is deliberately capped at $50B - we look for stocks with room to run. The cap does not apply to scanners that run without the global filters; that is noted below their hit list.
Net Margin
How much of revenue is left as profit? Net income divided by revenue, in percent. A 20% margin means: out of every dollar of revenue, 20 cents is left as profit. Rising margins are a strong quality signal.
Operating Cash Flow (OCF)
The cash that actually flows into the company from day-to-day operations - without accounting effects such as depreciation. A company can report book profits while still burning cash; operating cash flow reveals that.
Piotroski F-Score
A balance-sheet health check developed by Joseph Piotroski: 9 yes/no criteria covering earnings, cash flow, leverage, and efficiency produce a score from 0 to 9. Scores of 7 or higher are considered financially very solid, scores under 3 a warning sign.
Sector & Industry
Two levels of industry classification: sector is broad (e.g., Technology), industry is narrow (e.g., Semiconductors). Many strategies watch industry strength, because strong stocks are almost always found in strong industries.
Stage (Weinstein Stages 1-4)
Stan Weinstein divides every price chart into four stages: Stage 1 = basing (sideways after a downtrend), Stage 2 = uptrend (the only buying stage), Stage 3 = topping, Stage 4 = downtrend (avoid, or short candidate). Measured against the 30-week line (150-day moving average) and its slope.

View all terms in the Scanner Glossary

Hit List

Filter

Rating (traffic light)

Stage

Funda Rating

Piotroski

Columns

This scanner's columns

Extra columns

Tip: clicking a column header sorts the table by that column; a second click flips the direction.

Matt Caruso: Sales Leader
Symbol Earnings Avg/Y 3Y Volatility Stage Funda Rating Piotroski MktCap Industry AI Rating Deep Dive Deep-Dive Report Sector Price YTD 6 Mo. 1 Year Off High Price Target RS EPS Rating ADR 10D ADR 30D Beta P/E P/E (f) P/S P/B P/FCF PEG EV/EBITDA EBIT Margin Gross Margin Net Margin ROE ROA Debt/Eq Equity Ratio Sales +/Y Growth Score Div. Yield Payout Ratio Altman Z Inst. % Short % Analysts
AAOI Applied Optoelectronics, Inc. 08/06 +1,099 % ⚠ Wildest 10% 139 % Stage 2 C 53 4 of 9 5.5 $ Communication Equipment Sells AI — — Technology 69.10 $ +322.9 % +266.1 % +123.2 % −40.7 % +89.8 % 98 42 12.0 % 12.7 % 3.84 — 84.0 9.3 5.0 — 0.78 38.4 -8.6 % 28.9 % -9.6 % -6.1 % -2.7 % 0.16 70.6 % +82.8 % 5 0.0 % 0.0 % 7.6 68.3 % 16.9 % 3.7 (6)
LQDA Liquidia Technologies Inc 08/11 +241 % ⚠ Wildest 10% 110 % Stage 2 A 79 7 of 9 4.0 $ Drug Manufacturers - Specialty & Generic Neutral — — Healthcare 45.10 $ +114.7 % +109.9 % +100.4 % −1.7 % +19.0 % 98 42 6.2 % 6.4 % 0.61 257.7 10.9 8.9 35.9 26.6 — 21.4 46.3 % 92.5 % 30.7 % 28.2 % 27.0 % 1.70 27.0 % +1,031.2 % 6 0.0 % 0.0 % 2.9 70.2 % 17.5 % 4.3 (8)
ALAB Astera Labs, Inc. 08/04 — ⚠ Wildest 10% 99 % Stage 2 A 84 5 of 9 49.1 $ Semiconductors – — — Technology 258.70 $ +138.7 % +168.3 % +52.6 % −9.8 % +33.5 % 97 88 10.3 % 10.6 % 3.69 160.2 39.5 40.9 27.4 177.5 — 152.2 20.1 % 75.1 % 30.7 % 21.1 % 10.7 % — 90.0 % +115.1 % 9 0.0 % 0.0 % 19.1 73.0 % 6.9 % 4.1 (26)
CRDO Credo Technology Group Holding Ltd 09/02 +487 % ⚠ Wildest 10% 96 % Stage 2 A 85 7 of 9 28.1 $ Semiconductors Sells AI
Read
— Technology 151.00 $ +89.0 % +63.6 % -9.4 % −13.2 % +69.7 % 96 93 10.5 % 11.3 % 3.25 54.2 23.5 17.7 12.1 64.0 — 48.6 35.7 % 67.1 % 33.8 % 34.4 % 16.1 % 0.01 89.9 % +205.7 % 9 0.0 % 0.0 % 19.7 75.9 % 6.7 % 4.7 (20)
ARWR Arrowhead Pharmaceuticals Inc 08/06 +42 % 60 % Stage 2 D 36 3 of 9 8.4 $ Biotechnology – — — Healthcare 59.90 $ +20.3 % +14.8 % +50.1 % −6.2 % +82.6 % 96 58 4.9 % 5.1 % 1.30 — 111.1 12.6 13.8 — — 27.9 -191.6 % 100.0 % -47.8 % -42.4 % -8.1 % 2.24 27.1 % +23,258.2 % 7 0.0 % 0.0 % 5.1 88.6 % 10.6 % 4.6 (15)
TVTX Travere Therapeutics Inc 08/05 +82 % 62 % Stage 2 B 56 5 of 9 4.6 $ Biotechnology Uses AI
Read
— Healthcare 50.40 $ +46.4 % +44.7 % +68.7 % −1.8 % +48.1 % 96 42 3.6 % 4.6 % 1.14 — 33.3 7.8 45.9 65.1 — 836.8 -29.0 % 59.2 % -7.4 % -69.4 % -3.7 % 3.35 17.8 % +110.5 % 6 0.0 % 0.0 % -2.7 113.4 % 15.1 % 4.7 (15)
SITM Sitime Corporation 08/05 +172 % ⚠ Wildest 10% 85 % Stage 2 A 82 7 of 9 12.6 $ Semiconductors Sells AI — — Technology 447.10 $ +100.1 % +87.9 % +61.3 % −25.1 % +69.5 % 95 12 8.0 % 7.5 % 2.89 — 32.7 26.9 9.8 149.4 3.82 290.8 -4.2 % 58.7 % 3.0 % -2.6 % 0.0 % 0.00 89.6 % +61.2 % 5 0.0 % 0.0 % 16.1 89.0 % 7.5 % 4.5 (12)
SEPN Septerna, Inc. 08/10 — 65 % Stage 2 B 58 4 of 9 2.0 $ Biotechnology – — — Healthcare 44.00 $ +31.2 % +17.9 % +106.2 % −9.1 % +23.2 % 94 50 7.5 % 6.9 % 2.28 — 107.5 20.1 — 18.9 — 0.0 — 100.0 % -24.5 % -9.3 % -7.1 % — — +4,174.5 % 5 0.0 % 0.0 % 7.0 102.7 % 14.4 % 4.9 (10)
OUST Ouster, Inc. 08/06 +244 % ⚠ Wildest 10% 102 % Stage 2 B 59 6 of 9 2.0 $ Electronic Components Sells AI
Read
— Technology 29.70 $ +108.7 % +141.8 % -7.2 % −18.8 % +76.8 % 93 42 15.3 % 13.5 % 3.23 — 0.0 9.8 — — — -0.8 -39.6 % 46.6 % -26.0 % -25.2 % -10.7 % — 72.2 % +52.5 % 5 0.0 % 0.0 % -0.7 50.0 % 9.1 % 4.7 (6)
SEI Solaris Energy Infrastructure, Inc 07/22 +327 % 79 % Stage 2 B 69 5 of 9 7.0 $ Oil & Gas Equipment & Services Sells AI
Read
— Energy 70.70 $ +70.3 % +76.6 % +34.0 % −7.8 % +49.3 % 92 87 7.0 % 7.1 % 1.29 — 384.6 9.2 — — 0.94 23.7 25.8 % 49.9 % 7.2 % 8.7 % 4.1 % — 26.1 % +98.7 % 5 0.8 % 43.2 % 4.1 113.1 % 25.9 % 4.6 (14)
AXSM Axsome Therapeutics Inc 08/03 +58 % 43 % Stage 2 C 51 5 of 9 7.7 $ Biotechnology – — — Healthcare 144.40 $ +32.5 % +56.9 % +7.6 % −8.8 % +97.1 % 92 42 3.6 % 3.5 % 0.85 — 24.1 9.9 139.6 — — -14.8 -32.8 % 93.2 % -24.7 % -349.4 % -16.3 % 4.03 7.6 % +65.6 % 7 0.0 % 0.0 % -3.1 76.6 % 9.8 % 4.8 (22)
ETON Eton Pharmaceuticals Inc 08/06 +249 % 66 % Stage 2 B 63 7 of 9 1.4 $ Drug Manufacturers - Specialty & Generic – — — Healthcare 52.20 $ +98.0 % +116.2 % +193.1 % −2.4 % +38.0 % 92 26 4.8 % 5.7 % 0.90 — 21.6 13.6 48.6 98.1 — 68.9 — 61.4 % 12.0 % -5.4 % 11.9 % 0.40 — +104.9 % 8 0.0 % 0.0 % 0.7 65.4 % 8.9 % 5.0 (4)
ASTH Astrana Health Inc 08/06 +13 % 68 % Stage 2 B 62 5 of 9 1.8 $ Medical Care Facilities Uses AI
Read
— Healthcare 36.50 $ +66.1 % +79.3 % +10.1 % −0.5 % +40.8 % 89 87 3.6 % 3.8 % 1.03 — 9.7 0.5 — 19.2 — 12.7 3.0 % 10.5 % 1.1 % 5.7 % 3.8 % — 33.9 % +56.4 % 5 0.0 % 0.0 % 5.2 61.5 % 11.9 % 4.6 (11)
NRIX Nurix Therapeutics Inc 07/08 +30 % 53 % Stage 2 C 50 1 of 9 2.7 $ Biotechnology – — — Healthcare 26.80 $ -0.6 % +23.2 % +131.8 % −2.7 % +26.4 % 84 42 7.3 % 7.5 % 1.82 — 0.0 3.9 — 7.4 — 5.9 -1,479.4 % 52.4 % 42.0 % -61.4 % 21.1 % — 75.6 % +54.0 % 4 0.0 % 0.0 % 2.6 115.0 % 16.3 % 4.5 (14)
FTAI FTAI Aviation Ltd. 08/04 +283 % 65 % Stage 2 B 68 5 of 9 19.1 $ Aerospace & Defense – — — Industrials 187.30 $ +33.6 % +52.7 % +1.1 % −17.0 % +117.7 % 83 77 6.6 % 6.4 % 1.57 36.4 11.2 6.1 43.5 — 3.22 17.4 22.5 % 32.2 % 15.9 % 233.3 % 11.4 % 10.23 9.5 % +43.2 % 6 1.3 % 34.1 % 8.0 97.2 % 8.9 % 4.6 (11)
ARQT Arcutis Biotherapeutics Inc 08/05 +66 % 52 % Stage 3 B 74 6 of 9 4.1 $ Biotechnology – — — Healthcare 32.10 $ -9.5 % -9.1 % +26.4 % −16.0 % +24.2 % 77 42 4.7 % 4.6 % 1.58 — 31.8 8.8 21.7 104.3 — 85.3 -8.6 % 91.1 % 6.2 % -1.4 % 5.1 % 0.07 41.2 % +91.3 % 6 0.0 % 0.0 % -0.1 110.2 % 18.4 % 4.5 (8)
PTCT PTC Therapeutics Inc 08/06 +33 % 41 % Stage 2 C 48 2 of 9 5.0 $ Biotechnology – — — Healthcare 60.00 $ +8.1 % +4.1 % -4.3 % −3.4 % +55.3 % 75 42 4.7 % 4.0 % 0.49 — 22.3 4.3 1,259.2 — 0.81 20.5 16.5 % 50.0 % -3.8 % -7,740.1 % 2.5 % -2.19 -6.3 % +114.5 % 8 0.0 % 0.0 % 2.5 117.7 % 14.9 % 4.3 (16)
RYTM Rhythm Pharmaceuticals Inc 08/04 +170 % 46 % Stage 3 B 55 5 of 9 6.3 $ Biotechnology – — — Healthcare 92.60 $ -0.8 % -2.0 % -18.3 % −11.4 % +52.7 % 70 42 5.8 % 4.8 % 2.01 — 333.3 26.2 52.3 — — -12.6 -87.1 % 89.0 % -85.6 % -101.2 % -31.0 % 1.85 27.8 % +45.8 % 5 0.0 % 0.0 % -4.6 110.0 % 16.1 % 4.5 (19)
MDGL Madrigal Pharmaceuticals Inc 08/04 +39 % 44 % Stage 2 B 58 2 of 9 10.1 $ Biotechnology – — — Healthcare 430.40 $ -11.8 % -12.5 % +2.4 % −16.5 % +55.6 % 68 42 4.0 % 4.0 % -1.05 — 66.2 7.8 18.5 — — -8.3 -29.8 % 91.5 % -25.3 % -49.4 % -17.8 % 0.64 44.3 % +432.1 % 4 0.0 % 0.0 % 1.3 106.5 % 12.2 % 4.7 (19)
AU AngloGold Ashanti plc 08/07 +103 % 60 % Stage 1 A 80 8 of 9 41.5 $ Gold Neutral — — Basic Materials 79.80 $ +1.1 % -6.4 % +21.0 % −38.6 % +33.9 % 66 90 5.7 % 5.6 % 0.74 11.6 12.3 3.7 4.7 10.4 0.78 6.5 56.1 % 54.8 % 32.2 % 43.0 % 24.9 % 0.27 54.4 % +70.8 % 7 5.3 % 58.6 % 10.2 80.6 % 1.0 % 4.1 (8)
ASTS Ast Spacemobile Inc 08/10 +321 % ⚠ Wildest 10% 108 % Stage 1 C 52 5 of 9 16.0 $ Communication Equipment – — — Technology 41.00 $ +0.3 % +11.2 % -46.6 % −51.0 % +77.8 % 62 42 10.4 % 11.6 % 2.71 — 0.0 138.8 6.0 — — -2.3 -1,014.0 % 38.9 % 0.0 % -37.8 % -7.6 % 1.44 34.4 % +1,505.2 % 4 0.0 % 0.0 % 5.9 47.2 % 21.7 % 3.4 (13)
BBIO BridgeBio Pharma Inc 08/04 +113 % 43 % Stage 1 B 59 3 of 9 14.7 $ Biotechnology – — — Healthcare 75.00 $ -10.3 % -5.9 % +6.2 % −18.0 % +55.3 % 59 42 3.7 % 4.0 % 0.97 — 0.0 15.5 134.1 — — -9.4 -54.5 % 94.4 % -97.0 % -1,789.7 % -26.0 % -1.49 -165.5 % +126.3 % 4 0.0 % 0.0 % -7.9 103.2 % 11.2 % 4.6 (23)
TARS Tarsus Pharmaceuticals Inc 08/05 +88 % 45 % Stage 4 B 59 3 of 9 3.1 $ Biotechnology – — — Healthcare 74.90 $ -19.2 % -25.8 % +9.9 % −24.5 % +38.1 % 56 42 4.6 % 4.6 % 0.45 — 70.9 5.1 8.9 55.3 — -3.2 -3.8 % 82.7 % -7.7 % -14.0 % -5.5 % 0.25 60.1 % +146.7 % 6 0.0 % 0.0 % 6.4 109.8 % 13.4 % 4.9 (10)

Price Chart

Quarterly Figures

No quarterly data available.

Frequently Asked Questions

Matt Caruso's sales screen: 12-month relative strength above 75, revenue growth in the latest quarter above 40%, 12-month revenue growth above 40%, price above $20, and average volume (50 days) above 150,000 shares — market leaders whose growth is accelerating AND that the market is already rewarding. Source: fundamental data.

All scanners are recalculated daily across the entire stock universe — most recently on November 2, 2026. The data basis is fundamental data and SEC filings (10-K annual reports and 10-Q quarterly reports).

Currently, 23 stocks pass this scanner's criteria (as of November 2, 2026).

Global filters: market cap of $50B or less (mega caps are cut from every scanner); 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); names after a reverse split (distorted price history) are excluded.

Related scanners

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?